The Quest for a Comprehensive Cancer Blood Test
The idea of a single blood test capable of screening for multiple types of cancers has intrigued oncologists for over a decade. Recent advancements in science have made strides in this area, with initial efforts focused on analyzing blood protein levels evolving to assessing tiny DNA fragments and utilizing algorithms to detect potential cancer indicators.
A noteworthy development is a blood test named Mercury, which demonstrated an impressive accuracy rate of 87% across 13 different cancers, including a 77% success rate for detecting stage 1 cancers. Dr. Aadel Chaudhuri, a radiation oncologist at Mayo Clinic, expressed amazement at these achievements, noting how he once deemed such a possibility unfeasible. He likened the challenge of identifying DNA from small tumors to searching for a specific car in a busy city.
Ultimately, the goal is to create a test that can reliably identify a range of cancers early enough to enable effective treatment, effectively saving lives. However, there was a setback earlier this year when the largest trial focusing on cancer blood tests did not meet its main goals. This trial, conducted by a company called Grail, sought to validate its Galleri test, which claims to identify over 50 cancer types by analyzing DNA fragments in the blood.
The trial results showed no significant decline in advanced cancer diagnoses among those who took the Galleri test when compared to those who did not. Chaudhuri remarked that while this was undoubtedly a setback, it might be premature to deem the entire trial a failure. Initial results indicated that, for certain cancers, the test did help in detecting them at earlier stages, potentially leading to a reduction in advanced-stage diagnoses.
Future Considerations for Survival Rates
Dr. Deb Schrag, a medical oncologist at Memorial Sloan Kettering Cancer Center, emphasized that for such multi-cancer blood tests to gain acceptance in the medical community, they must show effectiveness in saving lives. Grail plans to track patients from the trial for up to eight years to assess any impact on mortality rates. Schrag mentioned that if aggressive cancers are indeed releasing DNA into the bloodstream, early detection may not necessarily equate to improved treatment options.
Furthermore, the longer lifespan of patients with advanced cancers complicates the assessment of these tests’ effectiveness; it could take substantial time to determine their true impact on survival. Schrag pointed out that successful treatments have made trials more challenging to conduct.
Additionally, survival data could play a vital role in securing insurance reimbursement for these tests. Currently, none have received FDA approval, and Grail has been utilizing regulatory loopholes to market the Galleri test, predominantly making it available through high-end clinics for out-of-pocket payments.
Addressing Gaps in Cancer Screening
Despite a lack of survival data, these tests may still establish their worth by showing their ability to detect cancers that currently lack approved screening methods. Nickolas Papadopoulos from Johns Hopkins highlighted that while some cancers have effective screening practices, many significant types, including pancreatic cancer, do not.
As Papadopoulos awaits a detailed breakdown of the Galleri trial data, he is particularly curious about its success in identifying cancers not covered by standard screenings. Oncologists are also eager to evaluate how accurate the Galleri test was across different cancer types. Generally, performance can vary significantly; some tests have excelled in detecting ovarian cancers but struggled with breast cancers, for example.
This variation may stem from differences in how different tumor types release DNA into the bloodstream. Certain cancers, like kidney and early-stage prostate, may release less detectable DNA compared to others like pancreatic tumors.
There is optimism for future tests that might use a more comprehensive analysis of blood samples, integrating multiple data points to capture early-stage cancers more effectively. Schrag noted her excitement about the advancements in technology and believes we are on the verge of breakthroughs in this field.
However, it may be unrealistic to expect a single test to detect a wide range of cancers. Instead, Schrag envisions a future with multiple tests tailored to different cancer types, each serving a specific purpose within a broader screening framework.
The dream, as she describes it, is to have a simple blood test that can identify numerous cancer types. While that goal is ambitious, it may be more plausible to develop a series of targeted tests for various cancer categories.
